{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:17:39Z","timestamp":1789172259759,"version":"build-2803163510"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of the fixed\u2010ratio combination of insulin glargine 100\u2009U\/mL plus lixisenatide (iGlarLixi) with premixed insulin degludec plus insulin aspart (IDegAsp) according to the injection time of IDegAsp.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>The 24\u2010week, multicentre, randomised, open\u2010label Soli\u2010D study enrolled Chinese adults with type 2 diabetes (T2D) suboptimally controlled with oral antidiabetic drugs (OADs). This exploratory analysis evaluated glycaemic efficacy, body weight, basal insulin daily dose and hypoglycaemia outcomes with once\u2010daily iGlarLixi (injected before breakfast) versus IDegAsp (injected before breakfast, lunch or dinner).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 582 participants, 291 received iGlarLixi, with injections self\u2010administered before breakfast, and 291 received IDegAsp, with injections self\u2010administered before breakfast (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009139), lunch (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954) or dinner (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200998). Glycated haemoglobin (HbA1c) reductions from baseline to Week 24 were greater with iGlarLixi than IDegAsp injected before lunch (least squares mean difference \u22120.24% [\u22122.3\u2009mmol\/mol]) or dinner (\u22120.29% [\u22123.2\u2009mmol\/mol]), and slightly greater than IDegAsp injected before breakfast (\u22120.12% [\u22121.3\u2009mmol\/mol]). Average 2\u2010h postprandial glucose (2\u2010h PPG) reductions were also greater with iGlarLixi than IDegAsp, regardless of injection time. iGlarLixi provided additional benefits, including reduced body weight, lower total insulin doses and less hypoglycaemia risk compared with IDegAsp in all injection\u2010time subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Once\u2010daily iGlarLixi, injected before breakfast, was associated with improved HbA1c control and greater average 2\u2010h PPG reductions compared with IDegAsp, regardless of injection time, in Chinese adults with T2D suboptimally controlled with OADs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70902","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:21:08Z","timestamp":1779772868000},"page":"6965-6972","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Time of Injection on the Efficacy and Safety of\n                    <scp>iGlarLixi<\/scp>\n                    Versus\n                    <scp>IDegAsp<\/scp>\n                    in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli\u2010D Study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3812-700X","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"first","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0315-0541","authenticated-orcid":false,"given":"Juan","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2954-9423","authenticated-orcid":false,"given":"Tong","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Sanofi  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Lauand","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Melas\u2010Melt","sequence":"additional","affiliation":[{"name":"Ividata Life Sciences  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-4072","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"International Diabetes Federation \u201cDiabetes Atlas \u201d2025 https:\/\/diabetesatlas.org\/resources\/idf\u2010diabetes\u2010atlas\u20102025\/."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S006"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S009"},{"key":"e_1_2_10_6_1","first-page":"16","article-title":"China Diabetes Prevention and Treatment Guidelines","volume":"17","author":"Chinese Diabetes Society","year":"2025","journal-title":"Chinese Journal of Diabetes"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14722"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14803"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15724"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15857"},{"key":"e_1_2_10_14_1","unstructured":"China Pharmaceutical Information Query Platform \u201cNovo Nordisk: Degludec and Aspart Insulin Package Insert \u201d2023 https:\/\/www.dayi.org.cn\/drug\/1157879.html."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.34.2.81"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14128"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01375-8"},{"key":"e_1_2_10_18_1","unstructured":"European Medicines Agency \u201cSuliqua (Insulin Glargine Plus Lixisenatide) Solution for Injection in Pre\u2010Filled Pen [Summary of Product Characteristics] \u201d2017 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/suliqua\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_19_1","unstructured":"Sanofi \u201cSoliqua (Insulin Glargine Lixisenatide Injection Pre\u2010Filled Pen) \u201d2023 https:\/\/www.sanofi.cn\/zh\/your\u2010health\/products\/soliqua."},{"key":"e_1_2_10_20_1","unstructured":"US Food and Drug Administration \u201cSoliqua 100\/33 (Insulin Glargine and Lixisenatide) Injection for Subcutaneous Use [Prescribing Information] \u201d2016 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/208673s018lbl.pdf."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.13307"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70902","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:44:20Z","timestamp":1789170260000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/dom.70902"],"URL":"https:\/\/doi.org\/10.1111\/dom.70902","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70902\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70902\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70902\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70902\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70902\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70902\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70902\/v1\/review3","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2026-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}